Axsome Therapeutics shares made a handy gain on Wednesday after the firm announced that it has completed patient enrollment in its Gemini study, a Phase 3 trial of AXS-05 in...
Gainers: Wins Finance Holdings (NASDAQ:WINS) +102%. SAExploration Holdings (NASDAQ:SAEX) +50%. Atossa Genetics (NASDAQ:ATOS) +33%. Diebold Nixdorf (NYSE:DBD) +28%. Professional...
Axsome Therapeutics Inc (NASDAQ:AXSM) was acting great. It actually broke out mid-Sept, ran up, formed a flag, and it looked like it was going to fly, but the biotech’s got...
Investors in Axsome Therapeutics, Inc. (NASDAQ:AXSM) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2019 $22.50...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Buy||Buy||Buy||Strong Buy|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||1W||1||Oct 06, 2019|
|Doji Star Bearish||1D||1||Oct 16, 2019|
|Advance Block Bearish||1H||3||Oct 17, 2019 12:00PM|
|Morning Doji Star||1D||4||Oct 11, 2019|
|Advance Block Bearish||15||8||Oct 17, 2019 01:45PM|
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.